Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential.

Literature DB >> 10407397

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential.

Abstract

The incretin hormone, glucagon-like peptide 1 (GLP-1) has many actions; namely: (1) it enhances all steps of insulin biosynthesis and potentiates glucose-induced secretion; (2) it seems to have trophic effects on pancreatic cells; (3) it inhibits glucagon secretion; (4) it inhibits hepatic glucose production and lowers blood glucose, but does not produce severe hypoglycaemia; (5) it inhibits postprandial gastrointestinal motility and secretion; and (6) it reduces appetite and food intake. Because of this, current research is focusing upon development of a clinically practicable therapy for type 2 diabetes mellitus based on GLP-1.

Entities: Disease Gene

Year: 1999 PMID： 10407397 DOI： 10.1016/s1043-2760(99)00157-5

Source DB: PubMed Journal: Trends Endocrinol Metab ISSN： 1043-2760 Impact factor: 12.015

Keyword Cloud
Cited

13 in total

Review 1. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors: J J Holst
Journal: Diabetologia Date: 2006-01-14 Impact factor: 10.122

Review 2. From gut changes to type 2 diabetes remission after gastric bypass surgeries.

Authors: Bing Li; Xinrong Zhou; Jiarui Wu; Huarong Zhou
Journal: Front Med Date: 2013-04-04 Impact factor: 4.592

3. In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies.

Authors: M C Sharma; S Jain; R Sharma
Journal: In Silico Pharmacol Date: 2017-10-23

4. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.

Authors: V Ionut; K Hucking; I F Liberty; R N Bergman
Journal: Diabetologia Date: 2005-04-14 Impact factor: 10.122

Review 5. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus.

Authors: Jeff Unger
Journal: Mayo Clin Proc Date: 2010-11-24 Impact factor: 7.616

6. Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats.

Authors: S D Primeaux; M J Barnes; H D Braymer; G A Bray
Journal: Int J Obes (Lond) Date: 2010-04-20 Impact factor: 5.095

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential.

Review 1. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Review 2. From gut changes to type 2 diabetes remission after gastric bypass surgeries.

3. In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies.

4. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones.

Review 5. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus.

6. Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats.

7. Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients.

8. The role of the gut hormone GLP-1 in the metabolic improvements caused by ileal transposition.

Review 9. Incretins, insulin secretion and Type 2 diabetes mellitus.

10. Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.